Follow
James Christopher Tarr
James Christopher Tarr
Unknown affiliation
Verified email at Vanderbilt.Edu
Title
Cited by
Cited by
Year
Discovery of 2-indole-acylsulfonamide myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods
NF Pelz, Z Bian, B Zhao, S Shaw, JC Tarr, J Belmar, C Gregg, ...
Journal of medicinal chemistry 59 (5), 2054-2066, 2016
1462016
Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease
BJ Melancon, JC Tarr, JD Panarese, MR Wood, CW Lindsley
Drug discovery today 18 (23-24), 1185-1199, 2013
1342013
Selective Activation of M4 Muscarinic Acetylcholine Receptors Reverses MK-801-Induced Behavioral Impairments and Enhances Associative Learning in Rodents
M Bubser, TM Bridges, D Dencker, RW Gould, M Grannan, MJ Noetzel, ...
ACS chemical neuroscience 5 (10), 920-942, 2014
1312014
Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100
NE Byun, M Grannan, M Bubser, RL Barry, A Thompson, J Rosanelli, ...
Neuropsychopharmacology 39 (7), 1578-1593, 2014
1212014
Highly reactive catalysts for aerobic thioether oxidation: The Fe-substituted polyoxometalate/hydrogen dinitrate system
NM Okun, JC Tarr, DA Hilleshiem, L Zhang, KI Hardcastle, CL Hill
Journal of Molecular Catalysis A: Chemical 246 (1-2), 11-17, 2006
842006
Monitoring the speciation of aqueous free chlorine from pH 1 to 12 with Raman spectroscopy to determine the identity of the potent low-pH oxidant
DP Cherney, SE Duirk, JC Tarr, TW Collette
Applied spectroscopy 60 (7), 764-772, 2006
742006
Monitoring the speciation of aqueous free chlorine from pH 1 to 12 with Raman spectroscopy to determine the identity of the potent low-pH oxidant
DP Cherney, SE Duirk, JC Tarr, TW Collette
Applied spectroscopy 60 (7), 764-772, 2006
742006
Discovery and biological characterization of potent myeloid cell leukemia‐1 inhibitors
T Lee, Z Bian, B Zhao, LJ Hogdal, JL Sensintaffar, CM Goodwin, J Belmar, ...
FEBS letters 591 (1), 240-251, 2017
622017
Enantioselective metallophosphite-catalyzed C-acylation of nitrones
MR Garrett, JC Tarr, JS Johnson
Journal of the American Chemical Society 129 (43), 12944-12945, 2007
592007
Optimization of potent and selective tricyclic indole diazepinone myeloid cell leukemia-1 inhibitors using structure-based design
S Shaw, Z Bian, B Zhao, JC Tarr, N Veerasamy, KO Jeon, J Belmar, ...
Journal of medicinal chemistry 61 (6), 2410-2421, 2018
542018
Lanthanum Tricyanide-Catalyzed Acyl Silane− Ketone Benzoin Additions
JC Tarr, JS Johnson
Organic letters 11 (17), 3870-3873, 2009
502009
Discovery of potent myeloid cell leukemia-1 (Mcl-1) inhibitors that demonstrate in vivo activity in mouse xenograft models of human cancer
T Lee, PP Christov, S Shaw, JC Tarr, B Zhao, N Veerasamy, KO Jeon, ...
Journal of medicinal chemistry 62 (8), 3971-3988, 2019
462019
Fragment-based screening of programmed death ligand 1 (PD-L1)
E Perry, JJ Mills, B Zhao, F Wang, Q Sun, PP Christov, JC Tarr, TA Rietz, ...
Bioorganic & medicinal chemistry letters 29 (6), 786-790, 2019
452019
Targeting selective activation of M1 for the treatment of Alzheimer’s disease: further chemical optimization and pharmacological characterization of the M1 positive allosteric …
JC Tarr, ML Turlington, PR Reid, TJ Utley, DJ Sheffler, HP Cho, R Klar, ...
ACS Chemical Neuroscience 3 (11), 884-895, 2012
452012
Lanthanum Tricyanide-Catalyzed Acyl Silane− Ketone Benzoin Additions and Kinetic Resolution of Resultant α-Silyloxyketones
JC Tarr, JS Johnson
The Journal of organic chemistry 75 (10), 3317-3325, 2010
382010
Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071
EP Lebois, GJ Digby, DJ Sheffler, BJ Melancon, JC Tarr, HP Cho, ...
Bioorganic & medicinal chemistry letters 21 (21), 6451-6455, 2011
362011
Challenges in the development of an M4 PAM preclinical candidate: the discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides
JC Tarr, MR Wood, MJ Noetzel, JL Bertron, RL Weiner, AL Rodriguez, ...
Bioorganic & medicinal chemistry letters 27 (13), 2990-2995, 2017
312017
Challenges in the development of an M4 PAM in vivo tool compound: the discovery of VU0467154 and unexpected DMPK profiles of close analogs
MR Wood, MJ Noetzel, MS Poslusney, BJ Melancon, JC Tarr, A Lamsal, ...
Bioorganic & medicinal chemistry letters 27 (2), 171-175, 2017
312017
Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5, 6-dimethyl-4-(piperidin-1-yl) thieno [2, 3-d] pyrimidine core
MR Wood, MJ Noetzel, JL Engers, KA Bollinger, BJ Melancon, JC Tarr, ...
Bioorganic & medicinal chemistry letters 26 (13), 3029-3033, 2016
312016
Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides
JC Tarr, MR Wood, MJ Noetzel, BJ Melancon, A Lamsal, VB Luscombe, ...
Bioorganic & medicinal chemistry letters 27 (23), 5179-5184, 2017
272017
The system can't perform the operation now. Try again later.
Articles 1–20